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Received 11 September 2007; received in revised form 24 January 2008; accepted 1 February 2008AbstractObjective: To determine overall and disease-related accuracy of the clinical/imagiological evaluation for pulmonary infiltrates of unknown
aetiology, compared with the pathological result of the surgical lung biopsy (SLB) and to evaluate the need for the latter in this setting.Methods:
We conducted a retrospective review of the experiences of SLB in 366 consecutive patients during the past 5 years. The presumptive diagnosis was
based on clinical, imagiological and non-invasive or minimally invasive diagnostic procedures and compared with the gold standard of histological
diagnosis by SLB. We considered five major pathological groups: diffuse parenchymal lung disease (DPLD), primitive neoplasms, metastases,
infectious disease and other lesions. Patients with previous histological diagnosis were excluded. Results: In 56.0% of patients (n = 205) clinical
evaluation reached a correct diagnosis, in 42.6% a new diagnosis was established (n = 156) by the SLB, which was inconclusive in 1.4% (n = 5). The
pre-test probability for each disease was 85% for DPLD, 75% for infectious disease, 64% for primitive neoplasms and 60% for metastases. Overall
sensitivity, specificity, positive and negative predictive values for the clinical/radiological diagnosis were 70%, 90%, 62% and 92%, respectively. For
DPLD: 67%, 90%, 76% and 85%; primitive neoplasms: 47%, 90%, 46% and 90%; metastases: 99%, 79%, 60% and 99%; infectious disease 38%, 98%, 53%
and 96%. Conclusions: Despite a high sensitivity and specificity of the clinical and imagiological diagnosis, the positive predictive value was low,
particularly in the malignancy group. SLB should be performed in pulmonary infiltrates of unknown aetiology because the clinical/imagiological
assessment missed and/or misdiagnosed an important number of patients.
# 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
Keywords: Lung biopsy; Clinical diagnosis; Diffuse parenchymal lung disease; Solitary nodules1. Introduction
Surgical lung biopsy (SLB) is often considered essential for
the definitive diagnosis of patients with undiagnosed or
incompletely diagnosed pulmonary lesions. The decision to
perform a biopsy or a wedge resection of a specific lesion is
based on the likelihood that the pathologic examination of
the tissue obtained will yield specific information about the
nature of the disease and that this information can be used to
modulate the treatment or to simply treat by complete
resection ab initio.
However, the development and refinement of more
sophisticated and accurate imaging and diagnostic methods,
such as positron emission tomography (PET), high resolution
computer tomography (HRCT) and bronchoscopic techniques
[1], complemented by minimally invasive diagnostic proce-§ Presented at the 21st Annual Meeting of the European Association for
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challenge the usefulness of SLB. Consequently, the value of
the biopsy on the diagnosis, treatment and outcome of these
patients has become even more controversial [2—5].
The purpose of the present study was: (1) to determine
the overall and disease-related accuracy of clinical and
imagiological diagnosis; (2) to compare the presumptive
clinical/imagiological diagnosis with the histological result
of SLB for indeterminate pulmonary lesions/infiltrates; and
(3) to evaluate the need and value of the SLB in this
setting.2. Material and methods
2.1. Patients
In the period from January 2000 through December 2005, a
total of 366 patients with undiagnosed or incompletely
diagnosed nodular or interstitial lung disease underwent
surgical lung biopsy or wedge resection, for diagnostic and/or
treatment purpose. Patients with solitary pulmonary nodulesSurgery. Published by Elsevier B.V. All rights reserved.
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diameter, completely surrounded by normal lung, without
associated atelectasis or adenopathy [6,7]), or other focal
pulmonary processes were included in the study. Patients
who had an established diagnosis on accepted histological
criteria prior to referral, or had a transbronchial (TBB) or
transthoracic (TTB) diagnostic biopsy were excluded.
Data were retrospectively retrieved from the patients’
records and included: demographic material (age, sex,
smoking status); clinical assessment (detailed medical,
family, occupational, immunological status and drug use
history); physiologic results (pulmonary function tests,
including spirometry, lung volumes and diffusing capacity
of carbon monoxide); imagiological data (standard chest X-
ray and CT and HRCT scans); bronchoscopic examination and
related procedures (bronchial lavage or transbronchial
biopsy); and microbiology culture results.
The ages of the patients ranged from 5 to 84 (mean, 54)
years and there was a slight male predominance. Other
clinical data are shown in Table 1.
The patients were classified according to their immuno-
competence status, resulting from (1) primary diagnosis of
malignancy for which the patient received chemotherapy,
radiation or surgical intervention; (2) organ transplantation
with immunosuppressive therapy; (3) collagen vascular
disease or other autoimmune diseases requiring corticoster-
oid or immunosuppressive therapy; (4) AIDS; and (5) chronic
renal failure. One hundred and twenty-four (33.8%) patients
were immunocompromised.
Surgical biopsy was performed under general anaesthesia,
by video-assisted thoracoscopic surgery (VATS) or a limited
open thoracotomy. The site and number of lung biopsy
specimens were determined by the findings on the chest X-
rays or the CT scans. If there was suspicion of diffuse
parenchymal lung disease (DPLD), specimens were obtained
in a triangular fashion, 2—3 cm in each margin, whenever
possible from two different lobes, including the transition
zone between macroscopically normal-appearing parench-
yma and macroscopic diseased lung. Areas of obvious severe
fibrotic reaction (honeycomb pattern on HRCT scan) were
avoided.
For VATS biopsy, 1 or 2 EndoGIA staples (Auto Suture
Company Division, U.S. Surgical, Norwalk, Conn) were used
to secure the pulmonary margins. For mini-thoracotomy, the
lung specimen was excised after clamping proximally, and
tissue was secured by a double running suture of 3-0 vicryl.
Conversion to lobectomy and local lymphadenectomy was
performed in 13 patients after obtaining extemporaneous
histopathological results.
Operative morbidity and mortality were recorded.Table 1
Patient characteristics
Characteristics DPLDa (n = 120) Lung metastasis (n = 87) P
Mean age (years)b 55.8  14.0 (17—77) 52.9  17.7 (12—79) 6
Male (%) 50.0 59.8 5
Smoking status (%) 37.5 26.4 4
Immunosuppressed (%) 30.8 97.7 1
Symptomatic (%) 67.5 12.6 2
a Diffuse parenchymal lung disease.
b Values given as mean  SD (range).2.2. Analysis
The presumed diagnosis based on clinical and imagiolo-
gical findings, made preoperatively, was compared to the
histological diagnosis obtained by lung biopsy and categor-
ized as: correct diagnosis (CD), new (incorrect) diagnosis
(ND), and inconclusive (INC).
For the final analysis, five major pathological groups were
considered: DPLD (occupational, granulomatous disorders,
idiopathic interstitial pneumonias and others); primitive
neoplasm; metastases; infectious disease; and other lesions.
The validity and accuracy of the clinical diagnosis were
investigated. Sensitivity (proportion of individuals with the
disease who have a positive test) and specificity (proportion
of individuals without the disease who have a negative test)
were determined as measures of validity. The predictive
value (positive and negative) was also determined to
ascertain whether or not an individual has the disease,
based on a positive test [8]. The pre-test probability was
defined as the probability of the target disease (pathological
groups designated) known before the result of the lung
biopsy. It was calculated as the proportion of patients with
the target disease out of all the patients with that specific
presumptive diagnosis (clinical/imagiological), both those
with and without the disease [9]. The probability of the
target disorder was calculated by the formula: P(D+) = D+/
(D+ + D), where D+ indicates the number of patients with
the target disorder and D indicates the number of patients
without the target disorder.3. Results
There was no operative mortality. Postoperative compli-
cations were rare, seven patients (1.9%) having experienced
prolonged (more than 5 days) air leakage. Chest tube
drainage was required for a median of 3 days (range, 1—10
days). The median hospital stay was 4 days (range, 1—12
days).
For the analysis specific to this work, we considered six
patterns of imagiological presentation (based on chest X-ray/
CT/HRCT) and related them to the histological diagnosis
(Table 2). The DPLD group had a more heterogeneous
imagiological pattern and the honeycombing and ground
glass were almost specific features of this disease. In the
malignancy groups (metastases and primitive neoplasms),
the nodular pattern was overwhelming, but in 8 patients with
primitive neoplasms the radiological features were mainly
reticular/micronodular and associated to undifferentiated or
bronchioloalveolar carcinomas. The classical pleural inden-rimitive neoplasm (n = 57) Other lesions (n = 46) Inconclusive (n = 5)
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Table 2
Radiological patterns





n (%) n (%) n (%) n (%) n (%)
Nodularb 18 15.0 81 93.1 44 77.1 13 54.2 27 58.7
Reticular/micronodular 46 38.3 1 1.2 8 14.0 7 29.2 8 17.4
Ground glass 37 30.8 — — — — 3 12.5 1 2.2
Honeycombing 7 5.8 — — — — — — 1 2.2
Condensation 10 8.3 3 3.5 3 5.3 1 4.2 3 65
Others 2 1.6 2 2.3 2 3.5 — — 6 13.0
a Diffuse parenchymal lung disease.
b Pleural indentation was a specific finding of this radiological pattern and almost exclusive of the primitive neoplasm group.
Table 3
Histopathological findings of malignant lung biopsies
Origin Histology N (%)tation associated with nodular lesions was also almost
exclusively present in the malignancy group, especially in
primary lung cancer, but was present in only one third of
these patients (n = 16).
The correlation between the clinical/imagiological and
the histopathological diagnosis is shown in Fig. 1. In 205
patients (56.0%) clinical/imagiological evaluation reached a
correct diagnosis (CD) and in 156 (42.6%) a new diagnosis was
obtained unexpectedly (new diagnosis — ND). Biopsy was
inconclusive (INC) in five patients (1.4%).
These results varied among different pathologies: For
DPLD: CD 76% (n = 80), ND 21% (n = 22) and INC 3%
(n = 3); primitive neoplasms: CD 46% (n = 27), ND 21%
(n = 32); metastases: CD60% (n = 86), ND40% (n = 57) and
INC3% (n = 1); infectious disease: CD53% (n = 9), ND47%
(n = 8); other lesions: CD 50% (n = 3), ND 50% (n = 3);
solitary pulmonary nodules: CD 59% (n = 36), ND 41%
(n = 25). SLB was also able to discriminate the various sub-
types of lung tumours encountered (Table 3), with con-
sequent different prognosis.
Overall sensitivity, specificity, positive and negative
predictive values for the clinical/imagiological diagnosis
were 70% (95% confidence interval, 65—75), 90% (CI, 88—91),
62.3% (CI, 57—68) and 93% (CI, 91—94), respectively
(Table 4). The values for each disease are also shown in
Table 4.
The pre-test probability was 85% for DPLD, 75% for
infectious disease, 64% for primitive neoplasms and 60% for
metastases, meaning that there was a good correlationFig. 1. Relationship between the clinical/imagiological and the pathological
diagnosis, globally and for each disease. DPLD — diffuse parenchymal lung
disease; SPN — solitary pulmonary nodules; DH — diagnostic hypothesis; CD —
correct diagnosis. Figures in the bottom indicate the percentage of correct
diagnosis made by the clinical evaluation.between the predicted probability and the observed
frequency in the case of the DPLD, less good in the
malignancy group.
SLB was able to define and characterise the most
prevalent diseases, such as pulmonary malignancies and
DPLD; it reached a definitive diagnosis in 94.8% of patients;
42.6% of the pathological findings were different from the
initially proposed diagnosis; 52.6% of the primary lung
cancers were detected unexpectedly; in 40.3% of patients
with an initial diagnosis of lung metastases, this was
excluded; and in 37% of patients with suspicion of DPLD a
specific diagnosis could only be made after SLB.4. Discussion
The decision of whether or not to perform a SLB is not
straightforward. The procedure is clearly indicated in cases
in which clinical or imagiological findings are atypical or when
the presumptive diagnosis has a low degree of certainty. The
predictive value of the clinical criteria largely depends on the
experience of the clinician and of the radiologist, but
considerable interobserver variability exists, even when
evaluations are performed by experts in the field [10]. ThesePrimary lung
cancer (n = 57)
Adenocarcinoma 25 43.9
Squamous cell carcinoma 6 10.5
Mixeda 5 8.8
Small-cell carcinoma 3 5.3
Undifferentiated carcinoma 3 5.3
Adenosquamous carcinoma 2 3.5





cancer (n = 87)
Colorectal 22 25.3








a In five cases the pathologist could not differentiate between adenocar-
cinoma and squamous cell carcinoma.
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Table 4
Clinical/imagiological diagnosis disease-related accuracy
Sensitivity (%) (95% CI) Specificity (%) (95% CI) PPV (%) (95% CI) NPV (%) (95% CI)
DPLDa 67 (57—75) 90 (85—93) 76 (67—84) 85 (80—89)
Lung metastases 90 (93—99) 79 (74—84) 60 (51—68) 99 (97—100)
Primitive neoplasms 47 (34—61) 90 (86—93) 46 (33—59) 90 (86—93)
Infectious disease 38 (20—59) 98 (95—100) 53 (29—76) 96 (93—97)
Overall 70 (65—75) 90 (88—91) 62 (57—68) 92 (91—94)
a Diffuse parenchymal lung disease.
Fig. 2. Specific interstitial lung diseases detected by lung biopsy.criteria led to misdiagnosis in about 40% of our cases.
Interobserver variability is reduced and diagnostic accuracy
is improved in cases in which a diagnosis is made with a high
degree of confidence [11,12].
In the daily practice, there are two different scenarios
presented to the thoracic surgeon. First, there are the
patients with diffuse pulmonary infiltrates. Usually referred
by chest physicians with a presumed diagnosis of interstitial
lung disorder, but where the clinical/radiological evaluation
cannot precise the diagnosis, without which the physician is
usually reluctant to initiate medical treatment (corticoids or
immunosuppressive medication) or alter the treatment
instituted. In this case, SLB is merely a diagnostic procedure.
Second, are those patients with a SPN or other focal
pulmonary lesions and the possibility of malignancy is the
main concern. Observation for growth, biopsy and resection
are the available options, simultaneously aiming at avoiding
delay in the diagnosis and treatment of lung cancer, false
negative results, and unnecessary resection of benign
lesions. In this situation, SLB is simultaneously a diagnostic
and therapeutic procedure.
On the other hand, despite the recent advances in imaging
techniques (contrast-enhanced CT, PET, CT + PET) and in the
refinement of minimally invasive diagnostic procedures (TTB,
TBB), these techniques still have limitations. Although CT
scanning is a sensitive imaging technique, it cannot prove
malignancy. In multiple series, 25—40% of malignant nodules
(SPN) weremisclassified as benign [13]. In our study, a correct
diagnosis was achieved in only 59% of the SPN. Even in fine-
needle aspiration cytology, the sensitivity varies from 71% to
97% and the specificity from 97% to 100% and inadequate
samples are obtained in 4—18% of the cases [14]. Despite the
already proven applicability of PET (sensitivity and specificity
for malignancy were 89—100% and 79—100%, respectively,
and diagnostic accuracy ranging from 89% to 100%), false-
negatives can occur, most notably in association with
bronchioloalveolar carcinoma, carcinoids and in tumours
less than 10 mm in diameter. Furthermore, false positives
have been reported in active lung diseases such as
granulomas, aspergillomas, active tuberculosis and abscesses
[15].
Despite the high specificity of the clinical diagnosis, the
sensitivity was quite low in our study (except for the
metastases group), as was the positive predictive value,
meaning that there were a significant number of patients in
whom a correct diagnosis would bemissed if a lung biopsy was
not performed. The high sensitivity for the lung metastases is
misleading, because it was a diagnostic hypothesis usually
considered in patients with a known history of malignant
tumours, hence the probability to miss the diagnosis was
minimal. But when we evaluated the probability that apatient had the disease based on a positive test (PPV), the
clinical diagnosis was not satisfactory (low PPV), reflecting an
important number of false-positives in this group. Conver-
sely, the negative predictive value was very high (99%),
reflecting a very small number of false-negatives and
resulting in that almost all metastases (except one from a
tumour of unknown origin) confirmed by pathological
examination were previously presumed by the clinical/
radiological evaluation.
Regarding the DPLD group, the result of the positive
predictive value (76%) can be deceiving, because this is a
heterogeneous group with more than 100 entities and several
diagnostic hypotheses were present under the cover of this
broad term. In a considerable number of patients (n = 57)
with suspicion of having DPLD, a specific diagnosis could only
be made after SLB (Fig. 2). SLB was also able to distinguish
the several clinicopathological entities of idiopathic inter-
stitial pneumonias, in accordance with the definition of the
American Thoracic Society and European Respiratory Society
[20], discriminating different prognosis (Fig. 3).
There are several reports in the literature analysing the
accuracy of a clinical and radiological diagnosis of idiopathic
pulmonary fibrosis (IPF) and other subsets of DPLD [10,16—
19]. Although Hunninghake et al. [10] reported that a clinical
diagnosis of IPF made by experts in DPLD has a high sensitivity
and specificity, they emphasised that lung biopsy should be
undertaken when the clinical picture is unclear or when
patients are thought to have conditions other than IPF. Raghu
and colleagues [16] found that clinical assessment combined
with HRCT scanning has a specificity of over 90% for the
diagnosis of IPF. However, the sensitivity was lower,
suggesting that if they relied solely on clinical/radiological
assessment they would have missed an important number
(nearly one third) of IPF.
We had a high specificity in this group, probably related to
the inclusion of focal pulmonary lesions that would
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Fig. 3. Differential diagnosis of the several clinical—pathological entities of
idiopathic interstitial pneumonias. NSIP — non-specific interstitial pneumonia;
DIP — desquamative interstitial pneumonia; COP — cryptogenic organizing
pneumonia; UIP — usual interstitial pneumonia; RB-ILD — respiratory bronch-
iolitis-associated interstitial lung disease.practically exclude the diagnosis of DPLD, and a reasonable
sensitivity of the clinical evaluation, consistent with other
studies. Our experience shows that SLB almost uniformly
results in a precise diagnosis. As the classification schemes for
DPLD become more complex [20], diagnostic accuracy
becomes a more pressing issue.
With regards to focal lesions or SPN, 55% of the nodules
excised were malignant, comparable to the incidence
reported in the literature [21,22]. Eighteen patients (22%)
had primary and 20 (34%) had secondary lung cancer. Wewere
probably overzealous in the approach to these patients,
because nearly 45% of the nodules excised were benign,
meaning that an observational strategy could have been
carried out in some cases.
Finally, there was not a sufficient size sample for the
infectious group to draw conclusions about the accuracy of
the clinical diagnosis, even though it is important to refer
that 15 unexpected diagnoses were made after SLB, mostly
from infection with BK, which is still endemic in our country.
Our study has several limitations that deserve further
discussion. Firstly, we have coupled two distinct groups of
patients (diffuse infiltrates vs focal infiltrates), which could
have altered the overall accuracy, especially in respect of the
specificity and NPV (high in our study). Secondly, this is a
retrospective analysis. All the patients included were
referred for SLB and it is difficult to know the real accuracy
of the clinical/imagiological evaluation because there surely
were patients treated conservatively and others with a
correct pathological diagnosis obtained by less invasive
diagnostic procedures (TBB, TTB), not included in our study.
Thirdly, not all patients originated from inside our institution.
Many were referred from other primary and secondary
centres and from isolated chest physicians, meaning that the
clinical and imagiological observation was not uniform for all
patients, with probable impact on accuracy.
In conclusion, SLB is a safe and accurate diagnostic tool for
pulmonary infiltrates of unknown aetiology, and, in our
opinion, remains the gold standard for undiagnosed or
incompletely diagnosed diffuse pulmonary disease.References
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